A recent prospective cohort study evaluating the antibody profile of 23 previously untreated pediatric patients with severe hemophilia A observed that 30% of participants developed persistent inhibitors and an additional 39% developed non-neutralizing antibodies during the first 50 exposure days to recombinant FVIII (13). This evidence concerns the gene F8 and hemophilia A.